• Growth monitoring needs to be improved in renal failure patients.
• 12 patients need discussing jointly by the nephrology and endocrinology teams and considering for GH.
• Patients on or who have had GH are managed appropriately.
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Background
• Chronic renal failure can cause significant growth impairment.
• Many factors contribute towards growth failure and it has a significant impact on morbidity, mortality and quality of life.
• Growth failure defined as <2 nd centile for height o 29% of children who undergo renal transplantation are <2 nd centile for height o 41% of children on dialysis are <2 nd centile for height
• Patients who undergo renal transplantation experience some 'catch-up' growth but most patients do not reach their target height.
• It is important that growth is monitored regularly and growth failure addressed, including offering patients growth hormone (GH) where appropriate.
Aim
We appraised our current practice to see how well we are monitoring growth in renal failure patients and if we are offering GH to eligible patients.
Method
We defined standards from NICE guidelines and Bristol guidelines endorsed by BSPED. We collected data from 76 patients on haemodialysis, peritoneal dialysis or post-renal transplant.
Impact on Practice
• 4 patients in the post-transplantation group (first group reviewed) have been offered GH and 2 families accepted it. 8 patients are currently being reviewed.
• Growth charts have been placed in all patient notes.
• Findings have been shared with the nephrology team in a local meeting to improve awareness.
Results
• 16/44 (36%) post-transplantation and 20/32 (62%) dialysis patients had growth failure as defined by height <2 nd centile, slightly higher than quoted in the literature (29% and 41% respectively).
• 53/76 had growth charts in their notes, and 39/53 had their height and weight plotted regularly.
• 12 patients were potentially eligible for GH and not previously offered it.
• 11 patients were on or had previously received GH and were managed in line with NICE guidance. 
Growth

Standards
• Every child should have a growth chart in their current notes
• Every child should have growth measured and plotted at least twice a year
• All children with growth failure who are suitable should be offered growth hormone
• Growth hormone should be stopped if:
• growth velocity increases less than 50% from baseline in the first year of treatment
• final height is approached and growth velocity is less than 2cm total growth in 1 year
• there are insurmountable problems with adherence
• final height is attained
